An overhaul of drug pricing in the US is partly to blame for two companies threatening to pull their products from Australia’s Pharmaceutical Benefits Scheme.
MS patients face losing cheap access to $30,000 drug
An overhaul of drug pricing in the US is partly to blame for two companies threatening to pull their products from Australia’s Pharmaceutical Benefits Scheme.